<DOC>
	<DOCNO>NCT01856881</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics follow ascend multiple dos AMG 876 subject type 2 diabetes .</brief_summary>
	<brief_title>Multiple Ascending Dose Study Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female subject ≥ 18 ≤ 65 year age time randomization Female subject must document nonreproductive potential Diagnosed type 2 diabetes HbA1c ≥ 6.5 % ≤ 10 % Fasting Cpeptide value ≥ 0.8 ng/mL Body mass index ( BMI ) ≥ 25.0 ≤ 40.0 kg/m2 screen Female subject lactating/breastfeeding plan breastfeed study 4 week receive last dose study drug . Male subject partner pregnant plan become pregnant subject study 4 week receive last dose study drug Evidence history screen diabetic complication significant endorgan damage , eg , proliferative retinopathy and/or macular edema , estimate glomerular filtration rate &lt; 60 mL/min/1.73m2 ( calculate use Modification Diet Renal Disease formula ) macroalbuminuria ( ie , ≥ +1 proteinuria urinalysis ) , diabetic neuropathy complicate neuropathic ulcer , severe autonomic neuropathy gastroparesis , chronic diarrhea , hypoglycemic unawareness Significant cardiac disease , include limited , evidence history coronary artery disease , unstable angina , congestive heart failure , know arrhythmias atrial ventricular etiology , unexplained syncope , syncope/seizures relate arrhythmia Uncontrolled hypertension ( systolic blood pressure ≥ 150 mmHg diastolic blood pressure ≥ 90 mmHg ) either therapy screening Triglycerides ≥ 500 mg/dL ( 5.64 mmol/L ) screen Hepatic liver enzyme ALT , AST , alkaline phosphatase ( ALP ) , total bilirubin ( TBIL ) level &gt; 1.5 time upper limit normal ( ULN ) screen Fasting blood glucose &gt; 270 mg/dL screen visit Positive human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HbsAg ) , hepatitis C virus antibody ( HepCAb ) An unstable medical condition , define hospitalize within 28 day day 1 , major surgery within 6 month day 1 , otherwise unstable judgment investigator ( eg , risk complication adverse event unrelated study participation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Type 2 diabetes</keyword>
</DOC>